NCT01873365

Brief Summary

The study aims to estimate the incidence of herpes zoster (HZ), proportion of postherpetic neuralgia (PHN) and the economic burden and impact on quality of life, in Japanese adults greater than or equal to sixty years of age.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
448

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2013

Geographic Reach
1 country

14 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 6, 2013

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 10, 2013

Completed
19 days until next milestone

Study Start

First participant enrolled

June 29, 2013

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 4, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 4, 2015

Completed
Last Updated

June 1, 2018

Status Verified

May 1, 2018

Enrollment Period

1.6 years

First QC Date

June 6, 2013

Last Update Submit

May 31, 2018

Conditions

Keywords

Quality of lifeHerpes zosterPostherpetic neuralgiaJapanPhysician-practiceAdultsHealth economics

Outcome Measures

Primary Outcomes (2)

  • Total number of HZ cases reported in the study area, overall and within a specific age-group and gender. The following age-groups will be considered: 60-69, 70-79 and ≥ 80 years of age.

    Approximately 1 year

  • Occurrence of HZ-associated PHN pain, persisting between 90 and 270 days after the initial visit for this study.

    Day 90 - Day 270

Secondary Outcomes (8)

  • Occurrence of HZ-associated hospitalisations.

    Day 0 - Day 270

  • Occurrence of HZ-associated any pain, persisting between 0 and 270 days after the initial visit for this study.

    Day 0 - Day 270

  • Anamnestic information, clinical parameters and complications related to HZ.

    Day 0 - Day 270

  • Direct medical, direct non-medical and indirect costs related to HZ.

    Day 0 - Day 90

  • Quality of life (QoL) assessment in HZ subjects.

    Day 0 - Day 90

  • +3 more secondary outcomes

Study Arms (1)

Prospective Group

Japanese adults, aged greater than or equal to sixty years, diagnosed with HZ.

Other: Data collection

Interventions

Case report forms (CRFs), logbooks and booklets.

Prospective Group

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Japanese adults, male or female, greater than or equal to sixty years of age, presenting with HZ at the participating sites.

You may qualify if:

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written informed consent obtained from the subject.
  • A male or female greater than or equal to sixty years of age, presenting with HZ at the time of enrollment.
  • HZ diagnosis.
  • Is the subject's first outpatient diagnosis for this HZ episode. OR
  • Took place up to seven days prior to the initial visit for the present study. Note: Recurrent HZ cases may be enrolled as new cases based on the investigator's clinical practice.

You may not qualify if:

  • Not applicable.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

GSK Investigational Site

Hokkaido, 084-0906, Japan

Location

GSK Investigational Site

Hokkaido, 084-0909, Japan

Location

GSK Investigational Site

Hokkaido, 084-0912, Japan

Location

GSK Investigational Site

Hokkaido, 085-0014, Japan

Location

GSK Investigational Site

Hokkaido, 085-0032, Japan

Location

GSK Investigational Site

Hokkaido, 085-0036, Japan

Location

GSK Investigational Site

Hokkaido, 085-0052, Japan

Location

GSK Investigational Site

Hokkaido, 085-0057, Japan

Location

GSK Investigational Site

Hokkaido, 085-0062, Japan

Location

GSK Investigational Site

Hokkaido, 085-0063, Japan

Location

GSK Investigational Site

Hokkaido, 085-0805, Japan

Location

GSK Investigational Site

Hokkaido, 085-0813, Japan

Location

GSK Investigational Site

Hokkaido, 085-0822, Japan

Location

GSK Investigational Site

Hokkaido, 085-8533, Japan

Location

Related Publications (3)

  • Mizukami A, Sato K, Adachi K, Matthews S, Holl K, Matsuki T, Kaise T, Curran D. Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study. Clin Drug Investig. 2018 Jan;38(1):29-37. doi: 10.1007/s40261-017-0581-5.

  • Nakamura H, Mizukami A, Adachi K, Matthews S, Holl K, Asano K, Watanabe A, Adachi R, Kiuchi M, Kobayashi K, Sato K, Matsuki T, Kaise T, Curran D. Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan. Drugs Real World Outcomes. 2017 Dec;4(4):187-198. doi: 10.1007/s40801-017-0119-4.

  • Sato K, Adachi K, Nakamura H, Asano K, Watanabe A, Adachi R, Kiuchi M, Kobayashi K, Matsuki T, Kaise T, Gopala K, Holl K. Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice-based cohort study. J Dermatol. 2017 Apr;44(4):414-422. doi: 10.1111/1346-8138.13639. Epub 2016 Dec 5.

MeSH Terms

Conditions

Herpes ZosterNeuralgia, Postherpetic

Interventions

Data Collection

Condition Hierarchy (Ancestors)

Varicella Zoster Virus InfectionHerpesviridae InfectionsDNA Virus InfectionsVirus DiseasesInfectionsNeuralgiaPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Epidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • GSK Clinical Trials

    GlaxoSmithKline

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 6, 2013

First Posted

June 10, 2013

Study Start

June 29, 2013

Primary Completion

February 4, 2015

Study Completion

February 4, 2015

Last Updated

June 1, 2018

Record last verified: 2018-05

Locations